23:54 , Jun 14, 2019 |  BC Extra  |  Politics & Policy

June 14 P&P Quick Takes: Washington state approved for subscription HCV model; plus Merck and IBM, BGI, and more

Washington follows Louisiana in creating 'Netflix' model to buy HCV drugs  CMS approved Washington's Medicaid state plan amendment proposal to establish a subscription-based model for HCV drugs, under which the state would pay a fixed...
23:38 , Jun 11, 2019 |  BC Extra  |  Politics & Policy

New China regulations on genetic resources underscore flash point in U.S.-China tensions

Access to genomic data is becoming a flash point in geopolitical tensions between the U.S. and China as both sides are putting in place measures to restrict and scrutinize access to the data. As a...
00:33 , Jun 11, 2019 |  BC Extra  |  Politics & Policy

Senators call for HHS probe into CMS genetic testing payments to Chinese-linked companies

Sens. Charles Grassley (R-Iowa) and Marco Rubio (R-Fla.) have asked the HHS inspector general to investigate payments made by CMS to U.S. genetic testing companies that are partnered with companies that have ties to Beijing....
00:41 , Apr 6, 2019 |  BC Extra  |  Politics & Policy

CFIUS drawing line in sand on personal data

The Trump administration has further reinforced which kinds of life science investments will be off limits for foreign investors, as reports emerge that CFIUS is compelling two more Chinese firms to relinquish control over companies...
21:18 , Jan 9, 2019 |  BC Extra  |  Company News

Management tracks: Tak joins Flagship, Evercore taps Mehrotra

Paul-Peter Tak has stepped down from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) to join Flagship Pioneering as a venture partner. He was GSK's SVP of R&D, chief immunology officer and development lead. Evercore ISI hired Ravi Mehrotra...
02:12 , Dec 1, 2018 |  BioCentury  |  Politics, Policy & Law

China’s germline growing pain

How Chinese regulatory authorities respond over the long term to the CRISPR baby furor could influence its industry’s success on the global stage, as domestic and international stakeholders seek reassurance that the authorities are on...
17:01 , Oct 25, 2018 |  BC Innovations  |  Translation in Brief

Big debuts for big genomics

BGI Genomics Co. Ltd. (SZSE:300676) and UK Biobank Ltd. each made a splash this month with papers showcasing the wealth of information captured by their genomic data troves. Though the studies differed in design, technical...
22:46 , Oct 19, 2018 |  BioCentury  |  Politics, Policy & Law

CFIUS waiting game

Biotech and its investors must wait to find out how much of the industry will be caught up in the CFIUS dragnet of foreign investment in American companies, but the U.S. Treasury has given itself...
22:14 , Oct 11, 2018 |  BC Innovations  |  Strategy

Border security for China’s genomes

China’s policies on sharing genomic data have so far produced cumbersome but manageable hurdles for cross-border clinical trials and translational research. But the explosive growth of its genomics industry, and the backdrop of rising political...
01:14 , Oct 6, 2018 |  BioCentury  |  Finance

Large cap comeback

The biotech sector continued to be a stock pickers’ market through 3Q18 as there was a near even split between global biotech stocks that gained and lost value in the quarter. While 1H18 saw investors...